Q-omics provides the consensus-scored STK40 profile across patient tissues and cancer cell-line models. STK40 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, STK40 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, STK40 RNA expression shows 17,987 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, BLCA, and ACC as cancer lineages where STK40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK40 survival associations across molecular data types. STK40 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK40 RNA expression–survival associations across cancer types. High STK40 expression shows unfavorable associations in LGG, LIHC and BLCA, but favorable associations in HNSC, SCLC and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for STK40 RNA expression.
This table summarizes STK40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STK40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK40 shows lower tumor expression in BLCA, THCA, KIRP, LUAD, HNSC and BRCA. The BLCA box plot shows higher STK40 RNA expression in normal versus tumor tissue (log2 FC = −1.628, t-test p < 0.001).
This table shows molecular features associated with STK40 in patient tissues and cancer cell lines. In patient samples, STK40 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STK40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
